Invirsa, Inc

Invirsa, Inc is a biotechnology startup focused on developing a pioneering molecule, INV-102, designed to enhance ocular DNA repair and the innate immune response to infection and injury. The molecule has shown remarkable efficacy in animal models, particularly in ocular sulfur mustard gas injury, a condition with no approved therapy. In September 2020, they received a $29.6M BARDA award to support the clinical development of INV-102, covering activities up to Phase 3 clinical trials. Established in 2016 and headquartered in the United States, the company recently secured a $7.70M Series B investment on 14 June 2023 from prominent investors including CincyTech, Rev1 Ventures, JobsOhio, and JumpStart Ventures. With a commercial focus on infectious keratoconjunctivitis, Invirsa aims to address a significant unmet need in ocular health, particularly in treating the viral form of the disease, which constitutes the majority of cases.